SHENZHEN, Mar. 18, 2021 --MGI, a global life-science technology innovator, lends a hand to resource-restrained African countries in response to the surge of local COVID-19 cases. New COVID-19 variants have emerged in Africa causing growing concerns globally. In a recent study published in Nature, the scientists expressed fear that these new variants show less effects to the current vaccines, and reinfections may be more likely. The study also found that the South Africa variant has shown ...

SHENZHEN, Mar. 2, 2021 --WHO has called on many countries to “build and boost”genomic surveillance. MGI is actively joining hands with leading research collaborators contributing to the genomic surveillance in multiple countries.In March 2020, the Korea Institute of Basic Sciences RNA Research Center and Seoul National University released the high-definition mapping of the COVID-19 transcriptome and epigenetic transcriptome generated from MGI’s DNBSEQ-G50 platform. In Genomic Sequencin...

This “Local + mobile” one-stop nucleic acid testing platform consists of Guiyang Novel Coronavirus nucleic acid testing base (local lab) and MGI container lab (mobile lab). After sample preparation, the test results are available in 4 hours. Guiyang Center for Disease Control and Prevention Guiyang City Testing Base - MGI Three Platforms Providing Powerful Technology support Thanks to the integrated package of MGISTP-7000 high-throughput automated sample transfer processing system com...

In response to the interim ruling by the Hong Kong High Court on 25 February 2021 regarding Illumina’s patent lawsuit against MGI, MGI makes the following statement: MGI welcomes the court’s decision not to issue an injunction. We respect the court’s judgement and will abide by the undertaking that we made to the court. It should be noted that we have initiated an antitrust lawsuit against Illumina in the United States as a result of its illegal acquisition of patents, and this lawsuit...

In 2019, MGI and YUCEBIO reached a strategic cooperation agreement “Over the last two decades, the field of oncology genomics has witnessed phenomenal growth that wouldn’t have been possible without the joint efforts from the oncology clinical genomic testing service companies. YUCEBIO is one of the leading companies in the field of tumor immunotherapy in China. We started our cooperation in 2018. We have witnessed the rapid development of YUCEBIO in the past two years, and we are glad ...

In response to the rulings of the Patents Court within the High Court of Justice for England & Wales on 18 February 2021, MGI makes the following statement: We welcome the Court’s decision to give us the permission to appeal the judgment, and we intend to file its appeal with the Court of Appeal. As permitted by the Court, we will continue to supply sequencing reagents to our existing customers in the UK during the appeal period. Although MGI is appealing aspects of the judgement, it...